London, May 12, 2026, 22:28 BST
- British American Tobacco shares jumped 5.82% in London to £46.34, outperforming a mostly stagnant FTSE 100. Over in New York, the U.S. ADR closed around $63.64, gaining about 5.3%.
- BAT’s Vuse and Velo plans suddenly faced sharper scrutiny after the FDA shifted its approach on certain e-cigarette and nicotine pouch items.
- A U.S. judge tossed BAT’s North Korea sanctions case, following the company’s deferred prosecution deal and its roughly $630 million payment.
British American Tobacco didn’t jump on earnings news this time. Instead, shares surged as investors caught a break on both U.S. nicotine regulation and legal headwinds. BATS wrapped up in London at £46.34, notching a 5.82% gain, even as the FTSE 100 edged down 0.04%. The ADR in New York also finished strong at $63.64.
Trading kicked off in London at 4,393p, and by the close, the stock was sitting at 4,634p. That’s a sharp move for a consumer staple with BAT’s profile. This wasn’t just buyers chasing a bit more yield. What the price action really reflects: investors are taking a fresh look at the chances for BAT’s U.S. smoke-free business to gain ground in a calmer market.
The FDA says it won’t make enforcement a top priority for certain unauthorized electronic nicotine delivery systems and oral nicotine pouch products, as long as applications are on file and accepted—and if those applicants meet specific conditions. A PMTA, or premarket tobacco application, remains the required ticket for legally launching a new tobacco product. For investors, here’s what matters: established companies with proper filings and compliance resources have the clear edge over smaller outfits and illegal imports.
BAT flagged this as the key battleground for investors. Back in February, Chief Executive Tadeu Marroco warned about “illicit proliferation” clouding the Vapour category and pointed to Vuse as a likely winner if “stronger enforcement” came through. Now, the FDA’s latest move stops short of greenlighting BAT’s lineup, but for the market, it finally sketches out which way enforcement could swing. Bat
This shift matters: BAT is no longer just about Lucky Strike, Dunhill, and Camel fueling the bottom line. The company said smokeless products made up 18.2% of total revenue in 2025, while Velo Plus posted triple-digit growth. Velo also climbed to the No. 2 spot in the U.S. for both volume and value share. New Categories revenue rose 7.0% over the full year, picking up speed with double-digit gains in the back half.
The other catalyst was legal: U.S. District Judge Beryl Howell tossed the government’s criminal case accusing BAT of selling cigarettes to North Korea, Reuters said. The move came after BAT wrapped up a three-year deferred prosecution deal and paid its penalty. With the case gone, investors saw a lingering tail risk lifted—one of those unlikely but nasty threats that can drag on a stock.
The bull thesis on BAT looks more pointed. There’s regulatory upside tied to Vuse, solid traction for Velo, and a £1.3 billion buyback scheduled for 2026. The company is sticking to a 3% to 5% constant-currency revenue growth outlook—so, not factoring in FX moves. On the balance sheet side, management sees leverage dropping to their 2.0 to 2.5 times target range by the end of 2026, bolstering the case for both dividends and that planned buyback.
The bear case hasn’t disappeared. The FDA made clear: products under the new enforcement policy are still unauthorized, and being included doesn’t guarantee premarket approval down the line. BAT is guiding for 2026 at the lower end of its medium-term outlook, with global cigarette industry volumes expected to fall around 2%. Currency pressures remain in the mix.
The peer read-through highlights the sector’s split tone. Philip Morris advanced 2.65%, with Altria up 1.87% on Tuesday; Imperial Brands managed a gain in London trading as well, even after it fell short of first-half profit forecasts and flagged cost pressures stemming from the Iran war. This was a targeted move into the sector—not indiscriminate buying. Investors chased U.S.-exposed nicotine stocks with regulatory momentum, but didn’t let weaker execution slide.
For BAT, the surge today looks more like a shakeup in how investors judge risk than any shift in fundamentals. What comes next? Eyes on the FDA’s public list of products, plus whether illegal disposables actually start to disappear from stores. Vuse, too—can it turn a regulatory window into real share growth? For now, the stock has taken off ahead of the facts. It’s up to the data to justify the move.
